Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Juli 2017 07:00 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs

AMES, Iowa, July 10, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it has received a Notice of Allowance for U.S. patent application number 15/171,031 from...
07. Juli 2017 07:00 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics to Host Its Second Quarter 2017 Financial Results Conference Call on July 28, 2017

AMES, Iowa, July 07, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today announced that it will release its second quarter 2017 financial results on Friday, July 28, 2017. The...
23. Juni 2017 07:00 ET | Quelle: NewLink Genetics Corporation

Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Presented at the European Hematologic Association (EHA) Congress in Madrid, Spain

AMES, Iowa, June 23, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the presentation of data from the Phase 1b portion of a study of indoximod, an IDO pathway...
08. Juni 2017 07:00 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics to Regain Rights to GDC-0919

AMES, Iowa, June 08, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that on June 6, 2017, Genentech, a member of the Roche Group, informed NewLink Genetics that...
05. Juni 2017 09:00 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics’ Indoximod + PROVENGE® Results in Statistically Significant Improvement in Radiographic Progression-Free Survival (rPFS) for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) in Phase 2 Trial

AMES, Iowa, June 05, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announces the presentation of results from a randomized Phase 2 investigator initiated study with...
02. Juni 2017 16:01 ET | Quelle: NewLink Genetics Corporation

Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer

AMES, Iowa, June 02, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the results from a Phase 2 trial of indoximod in combination with taxane chemotherapy for...
18. Mai 2017 06:00 ET | Quelle: NewLink Genetics Corporation

Data from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress

AMES, Iowa, May 18, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that an abstract describing data from a clinical study of its IDO pathway inhibitor,...
17. Mai 2017 17:05 ET | Quelle: NewLink Genetics Corporation

Data from Clinical Studies of NewLink Genetics’ Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017

AMES, Iowa, May 17, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two clinical studies of its IDO pathway inhibitors, indoximod and...
08. Mai 2017 07:00 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics to Participate in Upcoming Investor Conferences

AMES, Iowa, May 08, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the following upcoming investor conferences:Bank of...
04. Mai 2017 08:00 ET | Quelle: NewLink Genetics Corporation

NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance

AMES, Iowa, May 04, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today reported consolidated financial results for the first quarter 2017, as well as progress in its clinical...

Vorherige Seite